Related Experiment Videos
Improved left ventricular function after short-term treatment with fructose-1,6-diphosphate: echocardiographic study
A M Grandi1, C Muggia, F Barzizza
1Department of Internal Medicine and Medical Therapeutics, University of Pavia-IRCCS, Italy.
Insights
Fructose-1,6-diphosphate (FDP) improved left ventricular function in heart failure patients. FDP showed greater benefits in ischemic heart disease compared to dilated cardiomyopathy.
Area of Science:
- Cardiology
- Cardiovascular Physiology
- Biochemistry
Background:
- Left ventricular dysfunction is a hallmark of heart failure.
- Idiopathic dilated cardiomyopathy and chronic ischemic heart disease represent significant causes of cardiac morbidity.
- Fructose-1,6-diphosphate (FDP) is an intermediate in glycolysis with potential metabolic benefits.
Purpose of the Study:
- To evaluate the effect of intravenous fructose-1,6-diphosphate (FDP) on left ventricular (LV) function.
- To compare the efficacy of FDP in patients with chronic ischemic heart disease versus idiopathic dilated cardiomyopathy.
Main Methods:
- A crossover study design was employed involving 15 patients (7 with ischemic heart disease, 8 with dilated cardiomyopathy).
- Patients received either 10 gm of FDP or saline placebo intravenously for three days.
- M-mode echocardiography was used to assess LV function before and after each treatment period.
Main Results:
- FDP treatment resulted in a significant reduction in LV end-diastolic and systolic dimensions (6%, P < 0.01).
- Peak lengthening rate of LV dimension in diastole and peak shortening rate of LV dimension in systole increased by 17% and 10% (P < 0.05), respectively.
- FDP appeared more effective in patients with ischemic heart disease than in those with cardiomyopathy.
Conclusions:
- Intravenous FDP administration improves left ventricular function in patients with heart failure.
- FDP demonstrates potential therapeutic value in managing cardiac dysfunction, particularly in ischemic heart disease.
Abstract:
The effect of fructose-1,6-diphosphate (FDP) on left ventricular function was assessed in seven patients with chronic ischemic heart disease and eight patients with idiopathic dilated cardiomyopathy. In a crossover study design each patient received 10 gm of FDP or saline placebo intravenously for three days. An M-mode echocardiographic assessment of left ventricular (LV) function was made before and after each treatment period. After FDP treatment, LV end-diastolic and systolic dimensions showed a 6% reduction (P less than 0.01), while peak lengthening rate of LV dimension in diastole and peak shortening rate of LV dimension in systole increased 17% and 10%, respectively (P less than 0.05). There was evidence that FDP was more effective in the patients with ischemic heart disease than in the patients with cardiomyopathy.